Research programme: dopamine D3 receptor agonists - Pfizer
Latest Information Update: 16 Jul 2016
At a glance
- Originator Pfizer
- Class Aminopyridines
- Mechanism of Action Dopamine D3 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Sexual function disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Sexual-function-disorders in USA (PO)
- 26 Mar 2009 Preclinical trials in Sexual function disorders in USA (PO)